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Abstract
Engineering enzymes capable of modes of activation unprecedented in nature will increase the
range of industrially important molecules that can be synthesized through biocatalysis. However,
low activity for a new function is often a limitation in adopting enzymes for preparative scale
synthesis, reaction with demanding substrates, or when a natural substrate is also present. By
mutating the proximal ligand and other key active site residues of the cytochrome P450 from
Bacillus megaterium (P450-BM3), we have engineered a highly active His-ligated variant of
P450-BM3, BM3-Hstar, that can be employed for the enantioselective synthesis of the
levomilnacipran core. This enzyme catalyzesthe cyclopropanation of N,N-diethyl-2-
phenylacrylamide (1) with an estimated initial rate of over 1000 turnovers per minute and can be
used under an aerobic environment. Cyclopropanation activity is highly dependent on the
electronics of the P450 proximal ligand, which can be used to tune this non-natural enzyme
activity.
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Enzymes in nature catalyze only a small subset of industrially-relevant chemical
transformations.1 Thus, increasing the number of activation modes accessible to enzymes is
an important goal in biocatalysis, green chemistry, and sustainable synthesis.2 Drawing an
analogy between the mechanism of monooxygenation catalyzed by cytochrome P450 and
transition metal-catalyzed carbene insertions, we hypothesized that an iron-carbenoid
intermediate could be generated at the enzyme’ sheme prosthetic group in the presence of
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diazo compounds. Staring from this hypothesis, we have developed methods for
intermolecular, enantioselective cyclopropanation of styrenes and N-H insertion of anilines
catalyzed by variants of P450-BM3.3 These enzymatic methods are attractive alternatives to
transition metal catalysiswith Rh-or Cu-complexes4 for cyclopropanation because
cytochrome P450s are genetically encoded, can be very stereoselective, and use inexpensive
and nontoxic Fe as the catalytic center.
One challenge to using enzymes for non-natural chemistry is that the activity is often low.3,5
Wild-type P450-BM3 has very low cyclopropanation activity, for example, and even the
best reported variants are still 10–100 times less active for styrene cyclopropanation than for
epoxidation or hydroxylation of their preferred fatty acid substrates.6,7 Although introducing
mutations at amino acid residues critical for native monooxygenation readily eliminates the
competing P450-catalyzed styrene epoxidation reaction, molecular oxygen severely inhibits
the desired cyclopropanation reaction.8 As a result, anaerobic procedures must be employed
to favor carbenoid transfer reactions. Another consequence of the relatively low activity for
cyclopropanation is that the transformation is limited to electron-neutral and electron-rich
alkenes.3a Increasing the activity of P450s toward these non-natural reactions would greatly
expand their utility as cyclopropanation catalysts for bench top synthesis of biologically
active molecules and even large scale industrial use.
Recently, we reported that mutation of the proximal Cys at position 400 in P450-BM3 to Ser
enabled cyclopropanation by whole cells expressing these proteins (Figure 1a).8 The Cys to
Ser mutation increased the protein redox potential by 140 mV, allowing efficient reduction
from the inactive Fe(III)-heme resting state to the Fe(II)-heme active catalyst in vivo.9
However, in addition to modulating redox potential, we reasoned that the axial ligand also
affects the electronics of the proposed iron-carbenoid intermediate and thus the inherent rate
of P450-catalyzedcyclopropanation. In particular, we hypothesized that by varying the axial
coordinating ligand we might discover a more active enzyme, which would enable
cyclopropanation of a broader range of substrates.
To test this, we have initially focused on variants of P450-BM3 bearing His, Met, Tyr, or
Ala at the proximal position (Figure 1b). This set represents a range of possible coordinating
heteroatom ligands, and His, Met and Tyr are found at the axial position of naturally
occurring heme proteins like horseradish peroxidase (HRP), cytochrome c, and catalase.10
We chose Alaas well because it is anarchetypal small amino acid and may allow a water or
hydroxide molecule to coordinate to the Fe center.11 To examine how the different axial
ligands affect cyclopropanation activity, we introduced all four axial mutations into the
wild-type holoenzyme containing one additional T268A mutation. This mutation was
previously found to be highly beneficial for cyclopropanation.3a Four variants, T268A-
AxX(where “X” denotes the single letter amino acid code of each axial variant), were
expressed as the His-tagged heme domains, purified and characterized by UV-Vis
spectroscopy. All four bound CO efficiently and provided distinct Fe(II)-CO absorbances in
the 414–422 nm range (Figure S1).
When we monitored the reactions of the four variants with styrene and ethyl diazoacetate
(EDA), we found thatT268A-AxH was highly active and catalyzed the cyclopropanation of
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styrene to greater than 50% conversion within 30 min (Figure 2). Both the Cys-ligated
T268A and the Ser-ligated T268A-AxS (enzymes having the AxS mutation were previously
denoted as “P411s” due to the characteristic Fe(II)-CO absorbance at 411 nm of AxS
proteins3b) exhibited much slower kinetics at the same protein concentration. T268A is not
expected to be highly active for cyclopropanation of styrene in vivo because its redox
potential in the absence of native substrates is more negative than that of biological
reductants (−410 mV versus −310 mV for NAD(P)H). Thus, the Fe(III) resting state cannot
be easily reduced to the Fe(II) active catalyst. However, the higher activity of T268A-AxM
and T268A-AxH mutants relative to T268A-AxSsuggests that, among variants that can be
reduced to Fe(II) by biological reductants, those that have more electron-donating axial
ligands are more active in vivo cyclopropanation catalysts.
Our finding that the cyclopropanation activity of BM3 variants increases when natural Cys-
ligation is replaced with His-or Ser-coordination contrasts what has been previously
observed for P450-catalyzed monooxygenation.12 Mutation of the proximal Cys to Ser or
His causes the monooxygenation activity of the enzyme to fall precipitously.13 We have also
observed that mutation of other highly conserved amino acids in the P450 active site, such
as the distal Thron the I-helix (T268 in P450-BM3) that facilitates multiple proton transfers
en route to compound I, also produces more active cyclopropanation catalysts. Thus
conserved amino acids required for activation of molecular oxygen are not necessarily
required for activation of diazo compounds. Indeed, mutation of the axial residue and other
conserved positions in heme proteins may allow us to develop new enzymes that are better
suited for carbenoid or nitrenoid modes of reaction.14
To showcase the improved activity of the T268A-AxX mutants, we wanted to develop a
method for cyclopropanation of electron-deficient olefins which have been challenging
substrates for transition metal catalysts.15 In particular, we hypothesized that an
enantioselectiveBM3 catalyst could be used for the cyclopropanation of 1 with EDA in an
expedient synthesis of the levomilnacipran core (Scheme 1). Levomilnacipran (Fetzima™)
is a selective serotonin and norepinephrine reuptake inhibitor that was recently approved by
the Food and Drug Administration for treatment of clinical depression.16 The more active
(1R,2S)-isomer of milnacipran,17 levomilnacipran is sold in enantiopure form. While
multiple syntheses of milnacipran and levomilnacipran have been described,18 none have
used intermolecular enantioselective cyclopropanation to construct the cyclopropane core of
the molecule. The most high yielding and efficient of the reported methods requires a series
of alkylations and thermal rearrangements that require strong alkali bases and operate at
temperatures in excess of 80 °C.15a,b A chemoenzymatic synthesis could constitute a mild
and energy-efficient alternative that is concise and highly convergent.
When we combined 10 mM 1 with 10 mM EDA in the presence of whole cells expressing
the axial variants, we found that T268A-AxH catalyzed the reaction to 81% yield with
6:94diastereoselectivity and 42% enantioselectivity for the desired product (Table 1, entry
2). T268A and hemin failed to provide the desired product in synthetically useful yields
(entry 6 and 7, respectively). Although variants T268A-AxA and T268A-AxS also showed
appreciable activity, they were less active and less enantioselective than the His mutant
when normalized for catalyst expression level. T268A-AxH is also more active when used
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as the the purified holoenzyme (Table S3). Interestingly, horseradish peroxidase, which is
naturally ligated by an axial His, is a poor catalyst for this reaction (Table 1, entry 8). This
suggests that heme His-ligation alone is not sufficient for catalysis and that theP450 fold is
privileged for this transformation. The changes in diastereo-and enantioselectivity observed
for the different axial mutants suggest that the amino acid that replaces the Cys axial ligand
can affect active site geometry as well as reactivity. When whole-cell catalysts expressing
T268A-AxH were purged with CO prior to addition of both substrates, no catalysis was
observed (entry 9). Furthermore, control cells transformed with pET-22b(+) vector without
the BM3 gene also failed to catalyze the reaction (entry 10).These controls indicate that a
folded His-ligated BM3 enzyme is the active catalyst.
To create a catalyst more enantioselective than T268A-AxH, we performed site saturation
mutagenesis at four active site positions that had been shown previously to affect selectivity
in cyclopropanantion or monooxygenation: F87, I263, L437 and T438. The libraries were
screened in 96-well plate format using whole cells and an oxygen quenching system
containing glucose oxidase and catalase in sealed plates (see Supporting Information for a
detailed description of the screening process). The enantioselectivity of each reaction was
determined using chiral supercritical fluid chromatography. Mutagenesis at positions F87
and I263 failed to produce variants with higher selectivity than the parent T268A-AxH. The
libraries at L437 and T438, however, yielded variants T268A-AxH-L437W and T268A-
AxH-T438W which catalyzed the reaction to 69 and 68% enantioselectivity, respectively.
Unfortunately, combining both Trp mutations at position 437 and 438 significantly reduced
the yield and decreased the enantioselectivity to 23%.
As T268A-AxH-L437W showed higher activity than T268A-AxH-T438W (Table S4), we
chose the former as parent for a second round of site saturation at two sites, V78 and L181.
These two positions are located in the same region of the BM3 active site as L437 but are
not located on the same helix or loop as L437. We identified two variants, T268A-AxH-
L437W-V78M and T268A-AxH-L437W-L181V,that showed improved enantioselectivity
relative to T268A-AxH-L437W (87% and 75%, respectively) without loss of reactivity.
V78M and L181V were combined in variant T268A-AxH-L437W-V78M-L181V (named
“BM3-Hstar”) which provided the desired product in greater than 92% yield with 92%
enantioselectivity and 98:2 diastereoselectivity.
When the reaction of 1 and EDA catalyzed by BM3-Hstar in E. coli whole cells was
monitored by gas chromatography, we found that the reaction reached greater than 80%
conversion within the first 10 min. This is much faster than what we had observed for
cyclopropanation of 1 with T268A-AxS (Figure S3). The reaction catalyzed by parent
T268A-AxH was also complete within the first 15 min, which shows that the AxH mutation
alone dramatically increases the rate of olefin cyclopropanation. An estimate of the initial
rate based on the first five minutes of reaction shows that catalysis proceeds at over 1000
turnovers per minute. Indeed, even underan aerobic environment, BM3-Hstar is able to
catalyze the reaction of 1 and EDA to 90% yield (compared to 92–98% for an anaerobic
control performed in parallel, Eq. 1) when cells expressing BM3-Hstar to 2.0µM are used.
This observation suggests that cyclopropanation of 1 out-competes catalyst inhibition or
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deactivation by molecular oxygen. No other BM3 variant has demonstrated this tolerance to
atmospheric oxygen in these non-natural reactions.
(1)
The reaction of 1 with EDA could be performed on preparative scale under aerobic
conditions to provide the levomilnacipran precursor in 93% conversion and 86% isolated
yield (204 mg) using preparative HPLC, a diastereomeric ratio of 98:2 and 92%
enantioselectivity. Cyclopropane 2, which could not be separated from unreacted 1 by
column chromatography, was readily reduced to the corresponding alcohol in the presence
of 1.5 equivalents of LiBH4 to provide alcohol 3 in 88% isolated yield, without loss of
enantioselectivity (Scheme 1). Elaboration of this key intermediate to levomilnacipran has
been well-documented and can be achieved in two facile and high-yielding steps.18c
Mutating the amino acid at the axial site of P450-BM3, we have identified a highly active
and enantioselective cyclopropanation catalyst for a challenging electron-deficient olefin.
Starting from a parent BM3 variant with His in position 400, we engineered BM3-Hstar
through two rounds of site saturation mutagenesis and recombination to catalyze the reaction
of 1 and EDA to 92% yield, 92% enantioselectivity and 98:2 diastereomeric ratio.
Remarkably, a single mutation at the axial position dramatically increases the reaction rate
such that these new variants can be used for cyclopropanation of 1 with EDA in an aerobic
environment with minimal loss of yield. Three additional mutations identified through site
saturation mutagenesis, L437W, L181V, and V78M, greatly enhanced the enantioselectivity
of the transformation and further improved the activity of the catalyst, demonstrating that
the cyclopropanation reaction of P450-BM3 scaffold can be readily tuned for a desired
substrate. The tolerance of P450-catalyzed cyclopropanation to amino acid substitution at
the axial position contrasts with the strict requirement for axial Cys for monooxygenation
activity. The P450 protein’s ability to accept other amino acids at this key position and still
bind heme will allow us to tune the electronics of the catalytic center and thereby access a
broader range of carbenoid-based transformations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(a) Ser-ligated heme in BM3enablescyclopropanationin vivo.3b (b) Proposed Ala-, Met-,
His-, and Tyr-ligated heme in AxX variants of BM3.
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Figure 2.
Reaction progress of in vivo cyclopropanation of styrene with EDA catalyzed by axial
variants of T268A.
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Figure 3.
Sequential site saturation mutagenesis at key active site positions in T268A-AxH variant led
to increased enantioselectivity for cyclopropanation of 1.
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Scheme 1.
Proposed formal synthesis of levomilnacipran using P450-catalyzed enantioselective
cyclopropanation in the key ring-forming step.
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